AML and MDS Following Radiation Therapy Are Similar to De Novo Disease and Differ from Other Therapy-Related Myeloid Neoplasms

被引：0
|
作者：
Nardi, V.
Kluk, M.
Attar, E.
Winkfield, K.
Hasserjian, R. P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
LABORATORY INVESTIGATION | 2011年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1322
引用
收藏
页码：309A / +
页数：2
相关论文
共 50 条
  • [21] Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
    Mithun Vinod Shah
    Abhishek A. Mangaonkar
    Kebede H. Begna
    Hassan B. Alkhateeb
    Patricia Greipp
    Ahmad Nanaa
    Michelle A. Elliott
    William J. Hogan
    Mark R. Litzow
    Kristen McCullough
    Ayalew Tefferi
    Naseema Gangat
    Mrinal M. Patnaik
    Aref Al-Kali
    Rong He
    Dong Chen
    Blood Cancer Journal, 12
  • [22] Therapy-related MDS after curative intensive therapy for de novo acute myeloid leukemia - An emerging clinical entity?
    Helas, S.
    Roellig, C.
    Duehrsen, U.
    Herbst, R.
    Schaich, M.
    Thiede, C.
    Mohr, B.
    Kramer, M.
    Trautmann-Grill, K.
    Von Bonin, M.
    Bornhaeuser, M.
    Ehninger, G.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2013, 37 : S139 - S139
  • [23] Genomics of therapy-related myeloid neoplasms
    Kuzmanovic, Teodora
    Patel, Bhumika J.
    Sanikommu, Srinivasa R.
    Nagata, Yasunobu
    Awada, Hassan
    Kerr, Cassandra M.
    Przychodzen, Bartlomiej P.
    Jha, Babal K.
    Hiwase, Devendra
    Singhal, Deepak
    Advani, Anjali S.
    Nazha, Aziz
    Gerds, Aaron T.
    Carraway, Hetty E.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Maciejewski, Jaroslaw P.
    Radivoyevitch, Tomas
    HAEMATOLOGICA, 2020, 105 (03)
  • [24] Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
    Yarosh, Rina
    Roesler, Michelle A.
    Murray, Thomas
    Cioc, Adina
    Hirsch, Betsy
    Nguyen, Phuong
    Warlick, Erica
    Poynter, Jenny N.
    CANCER CAUSES & CONTROL, 2021, 32 (03) : 241 - 250
  • [25] Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
    Rina Yarosh
    Michelle A. Roesler
    Thomas Murray
    Adina Cioc
    Betsy Hirsch
    Phuong Nguyen
    Erica Warlick
    Jenny N. Poynter
    Cancer Causes & Control, 2021, 32 : 241 - 250
  • [26] The syndrome of therapy-related myeloid neoplasms
    Larson, R. A.
    LEUKEMIA RESEARCH, 2013, 37 : S7 - S8
  • [27] Therapy-related myelodysplastic syndrome (t-MDS) following treatment of acute myeloid leukemia (AML)
    Arana-Yi, C.
    Block, A. W.
    Sait, S. N.
    Ford, L. A.
    Barcos, M.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Development of Molecular Mutations during the Evolution of Therapy-Related MDS and Therapy-Related AML
    Kern, Wolfgang
    Meggendorfer, Manja
    Alpermann, Tamara
    de Albuquerque, Andreia
    Haferlach, Claudia
    Schnittger, Susanne
    Haferlach, Torsten
    BLOOD, 2014, 124 (21)
  • [29] Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML
    Mushtaq, Rao
    Akbar, Faisal
    Khan, Israa
    Isom, Scott
    Pardee, Timothy
    Howard, Dianna S.
    Powell, Bayard L.
    BLOOD, 2018, 132
  • [30] Therapy-Related Myeloid Neoplasm Has a Higher Subclonal Mutation Burden Than De Novo AML
    Zheng, Gang
    Pallavajjalla, Aparna
    Haley, Lisa
    Lin, Ming-Tseh
    Eshleman, James R.
    Gondek, Lukasz
    Borowitz, Michael
    Duffield, Amy
    Burns, Kathleen H.
    Gocke, Christopher D.
    LABORATORY INVESTIGATION, 2017, 97 : 388A - 388A
12345